Profound Medical Corp

PROF

6.490USD

+0.170+2.69%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

Profound Medical Corp's Score

Industry at a Glance

Industry Ranking

93 / 205

Overall Ranking

243 / 4521

Industry

Healthcare Equipment & Supplies

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Positive+

Profound Medical Corp Highlights

StrengthsRisks

Profound Medical Corp. is a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue. It is commercializing TULSA-PRO, a technology that combines real-time magnetic resonance imaging (MRI), AI-enhanced planning, robotically driven transurethral ultrasound and closed-loop temperature feedback control. The TULSA procedure, performed using the TULSA-PRO system, has the potential of becoming a mainstream treatment modality across the entire prostate disease spectrum; ranging from low-, intermediate-, or high-risk prostate cancer; to hybrid patients suffering from both prostate cancer and benign prostatic hyperplasia (BPH); to men with BPH only; and also, to patients requiring salvage therapy for radio-recurrent localized prostate cancer. It is also commercializing Sonalleve, a therapeutic platform that is CE marked for the treatment of uterine fibroids and palliative pain treatment of bone metastases.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 59.86% year-on-year.

Growing

The company is in a growing phase, with the latest annual income totaling USD 10.68M.

Overvalued

The company’s latest PE is -4.89, at a high 3-year percentile range.

Institutional Selling

The latest institutional holdings are 12.65M shares, decreasing 16.87% quarter-over-quarter.

Higher Market Activity

The company has more investor interest, with a 20-day turnover ratio of 1.38.

Analyst Rating

Based on 5 analysts

Buy

Current Rating

11.563

Target Price

+82.95%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current financial score of Profound Medical Corp is 7.14, ranking 100 out of 205 in the Healthcare Equipment & Supplies industry. Its financial status is robust, and its operating efficiency is low.

Score

Industry at a Glance

Previous score

7.14

Change

0



Financials

10.00

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.38

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

2.93

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

8.16

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.23

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

The current valuation score of Profound Medical Corp is 7.49, ranking 80 out of 205 in the Healthcare Equipment & Supplies industry. Its current P/E ratio is -4.89, which is -45.51% below the recent high of -2.66 and -132.46% above the recent low of -11.37.

Score

Industry at a Glance

Previous score

7.49

Change

0

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 93/205

Relevant data have not been disclosed by the company yet.

The current earnings forecast score of Profound Medical Corp is 8.80, ranking 14 out of 205 in the Healthcare Equipment & Supplies industry. The average price target is 11.12, with a high of 12.00 and a low of 11.00.

Score

Industry at a Glance

Previous score

8.80

Change

0

Support & Resistance

Relevant data have not been disclosed by the company yet.

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current price momentum score of Profound Medical Corp is 6.13, ranking 162 out of 205 in the Healthcare Equipment & Supplies industry. Currently, the stock price is trading between the resistance level at 8.19 and the support level at 5.55, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.03

Change

0.1

Support & Resistance

Relevant data have not been disclosed by the company yet.

Institutional Confidence

Currency: USD Updated: 2026-02-06

Score

Industry at a Glance

Previous score

3.00

Change

0

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Gagnon (Neil)

3.35M

+531.45%

Fidelity Investments Canada ULC

1.89M

--

Gagnon Securities LLC

1.73M

-0.96%

BDC Venture Capital

1.22M

--

Letko, Brosseau & Associates Inc.

986.25K

-18.10%

Gagnon Advisors, LLC

896.67K

--

Royce Investment Partners

Star Investors

859.91K

+12.42%

Rosalind Advisors, Inc.

692.18K

--

Menawat (Arun Swarup Ph.D.)

637.05K

+2.15%

Timelo Investment Management Inc.

603.54K

-28.21%



1

2



The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Healthcare Equipment & Supplies domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Profound Medical Corp is 3.00, ranking 133 out of 205 in the Healthcare Equipment & Supplies industry. The company's beta value is 0.34. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.

Profound Medical Corp

PROF

6.49 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

LivaNova PLC

LIVN

8.61 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Cencora Inc

COR

8.47 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Becton Dickinson and Co

BDX

8.46 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

AxoGen Inc

AXGN

8.42 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Align Technology Inc

ALGN

8.42 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment